Cephalon Provigil ADHD Trial Failure Cuts Anesta Merger Value By One-Third
Executive Summary
Cephalon is experiencing stock hyperactivity disorder following a negative clinical trial report in a preliminary study of Provigil for use in ADHD.
You may also be interested in...
Cephalon Stays Focused On Provigil; ADHD Launch Will Boost Sales Force 40%
Cephalon expects to increase its sales force by 40% in the second half of 2005 in order to support an upcoming launch of Provigil (modafinil) for pediatric attention deficit hyperactivity disorder
Cephalon Stays Focused On Provigil; ADHD Launch Will Boost Sales Force 40%
Cephalon expects to increase its sales force by 40% in the second half of 2005 in order to support an upcoming launch of Provigil (modafinil) for pediatric attention deficit hyperactivity disorder
Cephalon Provigil Focus: Studying ADHD In Children, Filing Shift Work sNDA
Cephalon plans to meet with FDA to discuss clinical requirements for a Provigil attention deficit hyperactivity disorder indication following positive results from a Phase II pediatric study, CEO Frank Baldino, PhD, said